Compare Duke Energy Corp (DUK) vs Moderna, Inc. (MRNA) Price & Performance

Duke Energy (DUK) trades at $122.97, up 1.46% today, with a bearish technical signal but strong fundamentals. Recent earnings beat estimates for three consecutive quarters, with Q2 2026 EPS at $1.43 versus $1.30 expected. The company maintains solid profitability, with a net income margin of 15.78% and ROE of 10.01%. Cash flow trends show consistent operational strength, though investing outflows remain high due to infrastructure spending.

The outlook is mixed: analyst consensus is a Buy with a $136.17 price target, but technical indicators signal near-term caution. Key risks include regulatory scrutiny and high debt levels, while opportunities lie in data-center demand growth and dividend stability. Investors should weigh strong fundamentals against bearish technicals and macroeconomic headwinds.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.